Combined TLR2/4-Activated Dendritic/Tumor Cell Fusions Induce Augmented Cytotoxic T Lymphocytes

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Koido, Shigeo ^a   Homma, Sadamu ^a   Okamoto, Masato ^b   Namiki, Yoshihisa ^a   Takakura, Kazuki ^a   Takahara, Akitaka ^a   Odahara, Shunichi ^a   Tsukinaga, Shintaro ^a   Yukawa, Toyokazu ^a   Mitobe, Jimi ^a   Matsudaira, Hiroshi ^a   Nagatsuma, Keisuke ^a   Uchiyama, Kan ^a   Kajihara, Mikio ^a   Arihiro, Seiji ^a   Imazu, Hiroo ^a   Arakawa, Hiroshi ^a   Kan, Shin ^a   Komita, Hideo ^a   Ito, Masaki ^a   Ohkusa, Toshifumi ^a   Gong, Jianlin ^c   Tajiri, Hisao ^a   more..

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; DENDRITIC CELL VACCINE; INTERLEUKIN 12P70; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUCIN 1; PENICILLIN DERIVATIVE; PICIBANIL; POLYSACCHARIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR VACCINE;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL FUSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; PHARMACOLOGICAL BLOCKING; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; STREPTOCOCCUS PYOGENES; T LYMPHOCYTE ACTIVATION; TRAMETES VERSICOLOR; TUMOR CELL; UPREGULATION;

ANTIGENS, CD86; CANCER VACCINES; CELL FUSION; CELL LINE, TUMOR; DENDRITIC CELLS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MUCIN-1; PICIBANIL; PROTEOGLYCANS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84875033168     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059280     Document Type: Article

References (23)

1. Steinman RM, (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271-296.
2. Gong J, Chen D, Kashiwaba M, Kufe D, (1997) Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3: 558-561.
3. Koido S, Hara E, Homma S, Mitsunaga M, Takahara A, et al. (2007) Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells. J Immunol 179: 4874-4883.
4. Zheng R, Cohen PA, Paustian CA, Johnson TD, Lee WT, et al. (2008) Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res 68: 4045-4049.
5. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A, (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6: 769-776.
6. Lu H, Yang Y, Gad E, Wenner CA, Chang A, et al. (2011) Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res 17: 67-76.
7. Lu H, Yang Y, Gad E, Inatsuka C, Wenner CA, et al. (2011) TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clin Cancer Res 17: 6742-6753.
8. Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, et al. (2004) Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with active component of OK-432, a streptococcal preparation. Cancer Res 64: 5461-5470.
9. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J, (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343: 1122-1126.
10. Tanaka N, Gouchi A, Ohara T, Mannami T, Konaga E, et al. (1994) Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. A randomized trial. Cooperative Study Group of Preoperative Intratumoral Immunotherapy for Cancer. Cancer 74: 3097-3103.
11. Koido S, Hara E, Homma S, Namiki Y, Komita H, et al. (2010) Dendritic/pancreatic carcinoma fusions for clinical use: Comparative functional analysis of healthy- versus patient-derived fusions. Clin Immunol 135: 384-400.
12. Koido S, Gong J, (2013) Characterization of structure and direct antigen presentation by dendritic/tumor-fused cells as cancer vaccines. Anticancer Res 33: 347-354.
13. Liu L, Chahroudi A, Silvestri G, Wernett ME, Kaiser WJ, et al. (2002) Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med 8: 185-189.
14. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD, (1992) Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1. Cancer Res 52: 1386-1392.
15. Koido S, Homma S, Hara E, Namiki Y, Takahara A, et al. (2010) Regulation of tumor immunity by tumor/dendritic cell fusions. Clin Dev Immunol 2010: 516768.
16. Andreani V, Gatti G, Simonella L, Rivero V, Maccioni M, (2007) Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res 67: 10519-10527.
17. Shibata M, Nezu T, Kanou H, Nagata Y, Kimura T, et al. (2002) Immunomodulatory effects of low dose cis-Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer. Cancer Invest 20: 166-173.
18. Tamagawa K, Horiuchi T, Wada T, Bannai K, Ando T, (2012) Polysaccharide-K (PSK) may suppress surgical stress-induced metastasis in rat colon cancer. Langenbecks Arch Surg 397: 475-480.
19. Harada M, Matsunaga K, Oguchi Y, Iijima H, Tamada K, et al. (1997) Oral administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice. Int J Cancer 70: 362-372.
20. Huang A, Gilmour JW, Imami N, Amjadi P, Henderson DC, et al. (2003) Increased serum transforming growth factor-beta1 in human colorectal cancer correlates with reduced circulating dendritic cells and increased colonic Langerhans cell infiltration. Clin Exp Immunol 134: 270-278.
21. Jarnicki AG, Lysaght J, Todryk S, Mills KH, (2006) Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177: 896-904.
22. Ghorpade DS, Kaveri SV, Bayry J, Balaji KN, (2011) Cooperative regulation of NOTCH1 protein-phosphatidylinositol 3-kinase (PI3K) signaling by NOD1, NOD2, and TLR2 receptors renders enhanced refractoriness to transforming growth factor-beta (TGF-beta)- or cytotoxic T-lymphocyte antigen 4 (CTLA-4)-mediated impairment of human dendritic cell maturation. J Biol Chem 286: 31347-31360.
23. Mou HB, Lin MF, Huang H, Cai Z, (2011) Transforming growth factor-beta1 modulates lipopolysaccharide-induced cytokine/chemokine production and inhibits nuclear factor-kappaB, extracellular signal-regulated kinases and p38 activation in dendritic cells in mice. Transplant Proc 43: 2049-2052.